As Per Industry Estimates, The Value Of The Total Addressable Market For The Eye Drop In The Us Is Around Usd 130 Million For The 52 Weeks Ending June 12, 2022. Dr Reddy'S Laboratories On Saturday Said It Has Entered Into A Pact With Usbased Slayback Pharma To Acquire Rights Of A Medication To Relieve Redness Of The Eyes. The Company Has Inked A Licensing Pact With The Newjersey-Based Drug Firm To Acquire Rights In Brimonidine Tartrate Ophthalmic Solution 0.025 Per Cent, The Hyderabad-Based Firm Said In A Statement. The Company'S Product Is Equivalent To Lumify, An Over-The-Counter (Otc) Eyedrop, That Can Be Used To Relieve Redness Of The Eye Due To Minor Eye Irritations. The Agreement Also Provides Dr Reddy'S Exclusive Rights To The Product Outside The Us, Dr Reddy'S Laboratories Said. As Per Industry Estimates, The Value Of The Total Addressable Market For This Product In The Us Is Around Usd 130 Million For The 52 Weeks Ending June 12, 2022
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!